George Poste

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Beyond Ebola: lessons to mitigate future pandemics	2015	Carlos Castillo‐Chávez Roy Curtiss Peter Daszak Simon A. Levin Oscar Patterson‐Lomba Charles Perrings George Poste Sherry Towers
+	Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards	2012	George Poste
+ PDF Chat	Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development	2012	George Poste David P. Carbone David Parkinson Jaap Verweij Stephen M. Hewitt J. Milburn Jessup
+	Tumor heterogeneity and progression: conceptual foundations for modeling.	1996	Larry D. Greller Frank Tobin George Poste
+	The experimental and clinical implications of cellular heterogeneity in malignant tumors	1983	George Poste Russell Greig
+	On the genesis and regulation of cellular heterogeneity in malignant tumors.	1982	George Poste Russell Greig

Common Coauthors

Coauthor	Papers Together
Russell Greig	2
Stephen M. Hewitt	1
Oscar Patterson‐Lomba	1
J. Milburn Jessup	1
Larry D. Greller	1
Charles Perrings	1
Roy Curtiss	1
David Parkinson	1
Peter Daszak	1
David P. Carbone	1
Carlos Castillo‐Chávez	1
Simon A. Levin	1
Sherry Towers	1
Frank Tobin	1
Jaap Verweij	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	International Approaches to Advancing Biospecimen Science	2011	Helen M. Moore Carolyn C. Compton Joseph S. Alper Jimmie B. Vaught	2
+ PDF Chat	Development and Use of Integral Assays in Clinical Trials	2012	Richard L. Schilsky James H. Doroshow Michael LeBlanc Barbara A. Conley	2
+	Biomarker studies: a call for a comprehensive biomarker study registry	2011	Fabrice André Lisa M. McShane Stefan Michiels David F. Ransohoff Douglas G. Altman Jorge S. Reis‐Filho Daniel F. Hayes Lajos Pusztai	2
+ PDF Chat	Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use	2012	Paul M. Williams Tracy Lively J. Milburn Jessup Barbara A. Conley	2
+ PDF Chat	The economic impact of SARS in Beijing, China	2009	Philippe Beutels Na Jia Qing‐Yi Zhou Richard Smith Wu‐Chun Cao Sake J. de Vlas	1
+ PDF Chat	Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves	2010	Birgit Grund Caroline Sabin	1
+ PDF Chat	Adaptive human behavior in epidemiological models	2011	Eli P. Fenichel Carlos Castillo‐Chávez Michele Graziano Ceddia Gerardo Chowell Paula Andrea González Parra Graham J. Hickling Garth Holloway Richard D. Horan B. Morin Charles Perrings	1
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	1
+ PDF Chat	Merging Economics and Epidemiology to Improve the Prediction and Management of Infectious Disease	2014	Charles Perrings Carlos Castillo‐Chávez Gerardo Chowell Peter Daszak Eli P. Fenichel David Finnoff Richard D. Horan A. Marm Kilpatrick Ann P. Kinzig Nicolai V. Kuminoff	1
+ PDF Chat	Economic optimization of a global strategy to address the pandemic threat	2014	Jamison Pike Tiffany L. Bogich Sarah Elwood David Finnoff Peter Daszak	1
+	Emerging infectious diseases: the role of social sciences	2012	Craig R. Janes Kitty Corbett James H. Jones James Trostle	1
+	STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement	2011	V. Gallo Matthias Egger Valerie McCormack Peter B. Farmer John P. A. Ioannidis Micheline Kirsch‐Volders Giuseppe Matullo David H. Phillips Bernadette Schoket Ulf Strömberg	1
+ PDF Chat	Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations	2011	Sharon S. Hori Sanjiv S. Gambhir	1
+ PDF Chat	Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents	2010	Janet Dancey Kevin K. Dobbin Susan Groshen J. Milburn Jessup Andrew H. Hruszkewycz María Koehler Ralph E. Parchment Mark J. Ratain Lalitha Shankar Walter M. Stadler	1
+	Routine pharmacogenetic testing in clinical practice: dream or reality?	2007	Iris Grossman	1
+	Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement	2006	Jean W. Lee Viswanath Devanarayan Yu Chen Barrett Russell Weiner John Allinson Scott Fountain Stephen Keller Ira Weinryb Marie Green Larry Duan	1
+ PDF Chat	Global trends in emerging infectious diseases	2008	Kate E. Jones Nikkita Patel Marc A. Levy Adam Storeygard Deborah Balk John L. Gittleman Peter Daszak	1
+ PDF Chat	Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development	2012	George Poste David P. Carbone David Parkinson Jaap Verweij Stephen M. Hewitt J. Milburn Jessup	1
+ PDF Chat	Biomarker-Based Early Cancer Detection: Is It Achievable?	2011	William D. Hazelton E. Georg Luebeck	1
+ PDF Chat	Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials	2012	Donald A. Berry Roy S. Herbst Eric H. Rubin	1
+	On SARS type economic effects during infectious disease outbreaks	2008	Milan Brahmbhatt Arindam Dutta	1
+ PDF Chat	On SARS Type Economic Effects During Infectious Disease Outbreaks	2008	Milan Brahmbhatt Arindam Dutta	1
+	Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework	2001	Arthur J. Atkinson Wayne A. Colburn Victor G. DeGruttola David L. DeMets Gregory J. Downing Daniel F. Hoth John A. Oates Carl C. Peck Robert T. Schooley Bert Spilker	1
+ PDF Chat	Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031	2012	Soheil Meshinchi Stephen P. Hunger Richard Aplenc Peter C. Adamson J. Milburn Jessup	1
+	The Clonal Evolution of Tumor Cell Populations	1976	Peter C. Nowell̀	1
+	Quantifying factors for the success of stratified medicine	2011	Mark Trusheim Breon Burgess Sean X. Hu Theresa Long Steven D. Averbuch Aiden Flynn A Lieftucht Abhijit Mazumder Judy Milloy Peter Shaw	1